The U.S. Food and Drug Administration has approved mirikizumab as a treatment for ulcerative colitis (UC) based on a pair of groundbreaking trials led by Mount Sinai’s gastroenterology team. Mirikizumab is the first and only infusion treatment that selectively targets the p19 subunit of interleukin-23, which plays a major role in inflammation related to UC.